Dynamic Multistage Gastrointestinal Digestion Model Assessment of Microbial Fermentation Products of Collagen Hydrolysates

Presented by: Christina E. Larder With Michele Iskandar and Stan Kubow School of Human Nutrition McGill University

1st International Electronic Conference on Nutrients Nutritional and Microbiota Effects on Chronic Disease

Osteoarthritis (OA)

- Joint degeneration: \downarrow cartilage content
- In any joint but mainly
 - Hands, knees, hips and spine
- Symptoms
 - Pain, stiffness, \downarrow flexibility, swelling, bone spurs
- \uparrow OA prevalence
 - 11th most debilitating disease globally
- Affects 50% of people over 75 years old



Osteoarthritis Risk Factors



- Obesity

 → Inflammation
 → OA ↑ joint and body inflammation
- Dyslipidemia
- Diabetes
- Hypertension

Gut Microbiome – OA Connection

- Obesity \rightarrow OA
 - Inflammatory process driven by obesityrelated gut dysbiosis
- Treated using prebiotic fibers
 - Restored microbiome diversity
 - \downarrow systemic inflammation
 - \downarrow arthritic scores
- Restoring the gut microbiome = novel approach to address OA of obesity

JCI insight

Targeting the gut microbiome to treat the osteoarthritis of obesity

Eric M. Schott, ..., Robert A. Mooney, Michael J. Zuscik

JCI Insight. 2018;3(8):e95997. doi:10.1172/jci.insight.95997.

Research Article Inflammation Microbiology

Osteoarthritis Treatment Options

- Non-steroidal anti-inflammatory drugs (NSAIDs) for pain
- Physical therapy
- Synovial injections
- Surgery (last retort)
- Many have adverse effects
- Limited efficacy

- \rightarrow Common use of supplements/nutraceuticals
- Multiple clinical studies: oral use of collagen hydrolysates (CHs)
 - \downarrow joint pain
 - 个 mobility
 - ↑ cartilage synthesis



Bernado et al., (2012) Bruyère et al., (2012) Lugo et al., (2013) Kumar et al., (2015) Feliciano et al., (2017)

Collagen Hydrolysates (CHs)

- Industrially processed collagen
- Cocktail of peptides and amino acids
- Peptides further broken down during human digestion
 - \rightarrow smaller peptides and amino acids



Prebiotics

- Dietary components (fiber, protein, amino acids)
- Beneficial Δ in gut microbiota
 - Activity, composition, growth
- Several health benefits
 - Regulate inflammation
 - Antioxidant activity
 - \downarrow Symptoms associated with arthritis



Major Short Chain Fatty Acids (SCFAs)

- Products of gut microbial fermentation
- Biomarkers of gut health/overall health
- Major SCFAs
 - Acetic acid
 - Propionic acid
 - Butyric acid

• Functions

- \downarrow Inflammation
- Regulate appetite
- Maintain liver mitochondrial function

Health impact & functions not completely understood

Minor SCFAs

- Valeric, caproic and heptanoic acids
- Biofunctional roles not fully established
- Controversial effects on human health



Luu et al.,(2019), Yamashiro et al., (2017), Berenbaum et al., (2013)

Branched Chain Fatty Acids (BCFAs)

- Isobutyric, isopropionic, isovaleric, isocaproic acids
- Health impact of BCFAs unclear



Associated with 个 insulin resistance & obesity

> Sheflin et al.,(2015) Saresella et al., (2020) Utzschneider et al., (2016)

CHs as Prebiotics?

- Prebiotics \rightarrow fermented proteins, peptides and amino acids
- CHs: rich in peptides and amino acids
- Knowledge gap on whether CHs can act as prebiotics

Need to investigate colonic fermentation of CHs

Computer Controlled Dynamic Multistage Gut Digestion Model

Pancreactic Acid Solution Acid Base Acid Base Water Bath Food **Data Acqusition &** Control Software Small \sim \sim Ascending Descending Transverse Nitrogen Cylinder Stomach Refrigerator Effluent Colon Colon Intestine Colon

Human fecal matter



Kubow et al., (2017) Habib et al., (2020) submitted Gaisawat et al., (in preparation)

Gut models generate peptide profiles matching human gastric/duodenal aspirates after protein supplementation

Thuenemann et al., (2015)

Computer Controlled Dynamic Multistage Gut Digestion Model

2 Weeks

- Stabilization of colonic fecal matter
- Injection of GI food every 8h

Time 0h

- Sample collection (control)
- Injection of GI food (every 8 h)
- Injection of CH

Times 8, 16, 24h

• Sample collection

<u>3 days</u>

• Washout period/stabilization before next treatment

- Two bovine sourced CHs: CH-GL and CH-OPT (n=2/CH)
- Dose based on clinical studies (1200 mg)
- SCFAs and BCFAs: gas chromatograph with flame ionization detector

Kubow et al., (2017) Ekbatan et al., (2016) Habib et al., (2020) submitted Gaisawat et al., (in preparation)



↑ Propionic and Butyric Acids After Simulated Digestion and Microbial Fermentation of CH-OPT



No Δ in SCFAs After Simulated Digestion and Microbial Fermentation of CH-GL



↑ Valeric Acid After Simulated Digestion and Microbial Fermentation of CH-OPT



No Δ in Minor SCFAs After Simulated Digestion and Microbial Fermentation of CH-GL

Ascending Colon			
Time (h)	Valeric aid (mM)	Caproic acid (mM)	Heptanoic acid (mM)
0	0.00±0.00	0.00±0.00	0.00±0.00
8	0.00±0.00	0.00±0.00	0.00±0.00
16	0.00±0.00	0.00±0.00	0.00±0.00
24	0.00±0.00	0.01±0.01	0.00±0.00

No significant content or Δ in minor SCFAs after CH-GL digestion

↑ BCFA Isovaleric Acid After Simulated Digestion and Microbial Fermentation of CH-OPT



↓ BCFA Isobutyric Acid After Simulated Digestion and Microbial Fermentation of CH-GL



No Δ in SCFAs and BCFAs in Transverse and Descending Colon

- No Δ for CH-GL or CH-OPT
- Insufficient peptides survived to support microbial fermentation?



Implications of CH Fermentation on Human Health

- - But ↑ fecal propionate = ↑ risk of type
 2 diabetes
- Controversial health impact of valeric acid

- CH-OPT: Benefits of 个 SCFAs offset by corresponding 个 in BCFA?
 - ↑ gut exposure to BCFAs =

 $\boldsymbol{\uparrow}$ risk for diabetes and obesity

(two risk factors for OA)

No ↑ in SCFAs or BCFAs after CH-GL

= neither prebiotic or dysbiotic properties

Luu et al.,(2019) Lau et al., (2019) Utzschneider et al., (2016) Yamashiro et al., (2017) Berenbaum et al., (2013)

Final Remarks

• Limited published data on effects of food-derived peptides on the gut microbiome and microbial fermentation products

- 1st evidence that CHs lead to \uparrow SCFAs and BCFAs
 - Microbial metabolic activity depends on CH product
 - Are differences due to altered peptide and amino acid profiles resulting from different CH processing/purification processes?

Thank you

Acknowledgements









Thanks to Mohd Baasir Gaisawat (PhD Candidate) for support in operating the dynamic gut model